Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Ratjen

Showing results (21-30 of 385) with videos related to

Pageof 39
Sort By:
Current Pharmaceutical Design|January 11, 2012
Nitric oxide and L-arginine deficiency in cystic fibrosisHartmut Grasemann, Felix Ratjen
Pediatric Pulmonology|November 13, 2019
Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulatorsLucy Perrem, Felix Ratjen
Annals of the American Thoracic Society|December 30, 2022
Preventing Continuous Damage in Primary Ciliary Dyskinesia: Is Airway Inflammation a Potential Target?Dvir Gatt, Felix Ratjen
Expert Opinion on Emerging Drugs|February 1, 2014
Emerging drugs for cystic fibrosisReshma Amin, Felix Ratjen
The Cochrane Database of Systematic Reviews|November 16, 2012
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisValerie Waters, Felix Ratjen
The Lancet. Respiratory Medicine|June 6, 2022
COMBATing airway inflammation in infants with cystic fibrosisMargaret Rosenfeld, Felix Ratjen
Expert Opinion on Emerging Drugs|September 4, 2010
Emerging therapies for cystic fibrosis lung diseaseHartmut Grasemann, Felix Ratjen
The Cochrane Database of Systematic Reviews|November 3, 2015
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisValerie Waters, Felix Ratjen
Expert Review of Respiratory Medicine|September 15, 2015
Newborn screening for cystic fibrosisTanja Gonska, Felix Ratjen
The Cochrane Database of Systematic Reviews|October 6, 2017
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisValerie Waters, Felix Ratjen
Pageof 39

Showing results (21-30 of 385) with videos related to

Sort By:
Pageof 39
Current Pharmaceutical Design|January 11, 2012
Nitric oxide and L-arginine deficiency in cystic fibrosisHartmut Grasemann, Felix Ratjen
Pediatric Pulmonology|November 13, 2019
Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulatorsLucy Perrem, Felix Ratjen
Annals of the American Thoracic Society|December 30, 2022
Preventing Continuous Damage in Primary Ciliary Dyskinesia: Is Airway Inflammation a Potential Target?Dvir Gatt, Felix Ratjen
Expert Opinion on Emerging Drugs|February 1, 2014
Emerging drugs for cystic fibrosisReshma Amin, Felix Ratjen
The Cochrane Database of Systematic Reviews|November 16, 2012
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisValerie Waters, Felix Ratjen
The Lancet. Respiratory Medicine|June 6, 2022
COMBATing airway inflammation in infants with cystic fibrosisMargaret Rosenfeld, Felix Ratjen
Expert Opinion on Emerging Drugs|September 4, 2010
Emerging therapies for cystic fibrosis lung diseaseHartmut Grasemann, Felix Ratjen
The Cochrane Database of Systematic Reviews|November 3, 2015
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisValerie Waters, Felix Ratjen
Expert Review of Respiratory Medicine|September 15, 2015
Newborn screening for cystic fibrosisTanja Gonska, Felix Ratjen
The Cochrane Database of Systematic Reviews|October 6, 2017
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisValerie Waters, Felix Ratjen
Pageof 39